PMC:7441788 / 18703-18946
Annnotations
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T182 | 117-118 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T231 | 24-29 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T232 | 47-52 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T140 | 0-243 | Sentence | denotes | Observational study HCQ group: n = 811; no-HCQ group: n = 565 HCQ (600 mg/2 times on the first day, then 400 mg once a day for 4 days) No correlation between the HCQ use and significant higher or lower risk of intubation or death was observed. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
676 | 20-23 | Chemical | denotes | HCQ | MESH:D006886 |
677 | 43-46 | Chemical | denotes | HCQ | MESH:D006886 |
678 | 62-65 | Chemical | denotes | HCQ | MESH:D006886 |
679 | 162-165 | Chemical | denotes | HCQ | MESH:D006886 |
712 | 224-229 | Disease | denotes | death | MESH:D003643 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T65 | 224-229 | http://purl.obolibrary.org/obo/GO_0016265 | denotes | death |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
676 | 20-23 | Chemical | denotes | HCQ | MESH:D006886 |
677 | 43-46 | Chemical | denotes | HCQ | MESH:D006886 |
678 | 62-65 | Chemical | denotes | HCQ | MESH:D006886 |
679 | 162-165 | Chemical | denotes | HCQ | MESH:D006886 |
712 | 224-229 | Disease | denotes | death | MESH:D003643 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T140 | 0-243 | Sentence | denotes | Observational study HCQ group: n = 811; no-HCQ group: n = 565 HCQ (600 mg/2 times on the first day, then 400 mg once a day for 4 days) No correlation between the HCQ use and significant higher or lower risk of intubation or death was observed. |